Navigation Links
Omeros Announces Clinical Development Programs for OMS103HP and OMS302
Date:5/19/2011

reported outcomes measuring symptoms, pain, activities of daily living, sport and recreational activities and quality of life associated with the operated knee showed a sustained benefit through postoperative Day 90.

In the first quarter of 2011, Omeros announced that OMS103HP failed to meet pre-specified efficacy endpoints in a Phase 3 clinical program in patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. Omeros is unable to draw any conclusions about OMS103HP's effect in the Phase 3 ACL program due to confounding factors, and the Company has no plans to conduct additional ACL reconstruction trials at this time. The primary endpoint for Omeros' meniscectomy Phase 3 trials is different than that used in its ACL program. Accordingly, Omeros believes that the results of its ACL program do not affect the viability of its meniscectomy program.

Omeros' OMS302 Program

OMS302 is Omeros' PharmacoSurgery™ product candidate being developed for use during ophthalmological procedures including cataract and other lens replacement surgery. OMS302 is a proprietary combination of an anti-inflammatory API and an API that causes mydriasis (pupil dilation), each with well-known safety and pharmacologic profiles. FDA-approved drugs containing each of these APIs have been used in ophthalmological clinical practice for more than 15 years, and both APIs are contained in generic, FDA-approved drugs.

In a Phase 2b clinical trial that evaluated OMS302 in patients undergoing cataract surgery, OMS302 demonstrated clinically meaningful and statistically significant benefits in both prespecified co-primary endpoints – maintenance of intraoperative mydriasis and reduction of pain in the early postoperative period. OMS302 also reduced the frequency of complaints of moderate and severe pain.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to disc
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Corporation Reports First Quarter 2011 Financial Results
2. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
3. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
4. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
5. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
6. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
7. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
8. Omeros Announces Publication of Data From Antifibrinolytic Program
9. Omeros Licenses Novel Antifibrinolytic Agents
10. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
11. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Champions Biotechnology, Inc. (OTC ... with a predictive preclinical platform aimed at accelerating ... drugs, has established an exclusive licensing agreement with ... University,s wholly owned technology transfer company. The licensing ...
... Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series ... used to complete the company,s ongoing Phase I/IIa trial of ... to prepare for Phase IIb trials. The company anticipates reporting ... , The new funding brings the total raised to date ...
Cached Medicine Technology:Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer 2Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer 3Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer 4Bellicum Pharmaceuticals Announces $4.5 Million in New Funding 2
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
(Date:4/17/2014)... improves general blood flow and alleviates muscle soreness ... at the University of Illinois at Chicago. , ... in the Archives of Physical Medicine and ... function in people who had not exercised, suggesting ... their level of physical activity. , Improved circulation ...
(Date:4/17/2014)... found that India,s shocking rates of suicide are highest ... clinging to tiny smallholdings less than one hectare ... cotton and coffee, that are highly susceptible to global ... previous case studies that point to a crisis in ... of the nation,s economy during the 90s. Researchers say ...
(Date:4/17/2014)... April 17, 2014 Giving patients adrenaline after they suffer ... increase their prospects of surviving long-term, according to new ... number of patients who have a cardiac arrest get ... cardiac arrest for decades," said Dr. Steve Lin, an ... "Yet, despite advances in medical treatment, long-term survival rates ...
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
Breaking Medicine News(10 mins):Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2
... published this week in the New England Journal of ... patients with a specific genetic mutation benefit from the drug ... 15.9 months. In patients who responded, the drug stopped cancer ... with a BRAF V600 mutation, this drug is a breakthrough. ...
... emerging field of systems biology, UT Southwestern Medical Center researchers ... cell,s sense of direction and then confirmed those predictions in ... explain how mammalian cells establish the sense of direction necessary ... form of E. coli bacteria employ to hijack ...
... Mo. Many leading causes of death are ... activity. Adults in minority populations have lower levels ... deaths, according to the Department of Health & ... Missouri researchers found that minority adults who received ...
... By Steven Reinberg HealthDay Reporter , ... on Wednesday blocked implementation of an FDA mandate that ... images on packages of cigarettes. The proposed requirement ... set to kick in this September, would have emblazoned ...
... All children can benefit from going to preschool, especially those ... where parents don,t provide much mental stimulation, a new study ... from 600 families who were followed from age 2 until ... went to preschool did better once they started kindergarten than ...
... refuting a hypothesis can be as significant as proving ... elucidating how diseases proceed with a view toward preventing, ... scientists from spending precious years of effort exploring a ... Proceedings of the National Academy of Sciences , Munich-based ...
Cached Medicine News:Health News:Investigators predict, confirm how E. coli bacteria hijack cells' directional mechanism 2Health News:Fitness programs for minority adults lack cultural relevance, MU study finds 2Health News:Judge Blocks Plan for Graphic Cigarette Warnings 2Health News:Preschool Kids Best Prepared for Kindergarten: Study 2Health News:Observations refute widely held view on causal mechanism in ALS 2Health News:Observations refute widely held view on causal mechanism in ALS 3
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
NS2000 Bipolar Generator provides precise coagulation without tissue sticking....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: